Novel pyrimidine-2,4-diamine derivative suppresses the cell viability and spindle assembly checkpoint activity by

Anna-Leena Salmela1, Jeroen Pouwels, Jenni Mäki-Jouppila

  • 1VTT Technical Research Centre of Finland, Biotechnology for Health and Wellbeing, Turku, Finland.

Carcinogenesis
|October 30, 2012
PubMed

Insights

A novel pyrimidine-2,4-diamine derivative inhibits the spindle assembly checkpoint (SAC) by targeting Aurora B kinase. This leads to mitotic exit errors and suppressed cancer cell viability, suggesting potential anticancer applications.

Area of Science:

  • Cell Biology
  • Molecular Pharmacology
  • Cancer Therapeutics

Background:

  • The spindle assembly checkpoint (SAC) is crucial for accurate cell division, preventing errors that can lead to cancer.
  • Targeting mitotic machinery, including the SAC, is a promising strategy for developing novel cancer therapies.

Purpose of the Study:

  • To investigate the cellular effects of a novel pyrimidine-2,4-diamine derivative.
  • To determine the mechanism of action of this compound, particularly its effect on the SAC and mitotic progression.
  • To evaluate the compound's potential as an anticancer agent.

Main Methods:

  • Treatment of cycling cells with the novel pyrimidine-2,4-diamine derivative.
  • Analysis of mitotic arrest, spindle architecture, and cell division errors.
  • In vitro and cellular assays to assess inhibition of Aurora B kinase, Aurora A kinase, and tubulin.
  • Evaluation of polyploidy induction and cancer cell viability.

Main Results:

  • The compound induced rapid escape from mitotic arrest caused by lack of interkinetochore tension.
  • It disrupted mitotic spindle architecture, leading to transient M-phase arrest and forced mitotic exit.
  • The compound directly inhibited Aurora B kinase activity, causing precocious SAC inactivation, polyploidy, and suppressed cancer cell viability.
  • Off-target effects on Aurora A kinase and tubulin were also observed.

Conclusions:

  • The novel pyrimidine-2,4-diamine derivative acts as a SAC inhibitor through direct inhibition of Aurora B kinase.
  • Its ability to disrupt mitosis and suppress cancer cell viability highlights its potential as a novel anticancer pharmacophore.
  • Further development of this compound could lead to new mitosis-targeting cancer therapies.

Related Concept Videos

The Spindle Assembly Checkpoint02:19

The Spindle Assembly Checkpoint

The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...